Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.55 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.47 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.47 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.42 |
| ▸ | WNT3A | P56704 | 2/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | F2R | P25116 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.40 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.40 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6603074 | 0.87 | CTSS (0.53) | CTSSTAS1R3TAS1R1TAS1R2KAT6A | |
| SCHEMBL1950901 | 0.84 | CTNNB1 (0.57) | PDK2CNR2LMNAGAACTNNB1 | |
| SCHEMBL29410857 | 0.84 | CTNNB1 (0.57) | PDK2CNR2LMNAGAACTNNB1 | |
| SCHEMBL24450817 | 0.83 | PDK2 (0.44) | CTSSPDK2LMNAGAACTNNB1 | |
| SCHEMBL28798676 | 0.83 | CTSS (0.55) | CTSSPDK2CNR1CNR2LMNA | |
| SCHEMBL4868895 | 0.83 | CTSS (0.48) | CTSSTAS1R3TAS1R1TAS1R2KAT6A | |
| SCHEMBL1198865 | 0.83 | CTSS (0.48) | CTSSTAS1R3TAS1R1TAS1R2KAT6A | |
| Hydrochloric Acid SCHEMBL5819908 | 0.82 | CTNNB1 (0.55) | PDK2CNR2LMNAGAACTNNB1 | |
| SCHEMBL4104026 | 0.81 | CTNNB1 (0.43) | CTSSPDK2CNR2LMNAGAA | |
| SCHEMBL27711565 | 0.81 | TAS2R14 (0.49) | CTSSPDK2LMNAGAACTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022268209-A1 | DERIVATIVE HAVING PYRIMIDINE-FUSED CYCLIC STRUCTURE, AND USE THEREOF | 四川汇宇制药股份有限公司 | 2022-12-29 | — | — | WO | disclosed |
| CN-103635472-B | Serine/threonine kinase inhibitor | 阵列生物制药公司 | 2018-01-12 | — | — | CN | disclosed |
| CN-104245698-B | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL CO.,LTD. (JP) | 2016-11-30 | — | — | CN | disclosed |
| CN-103249721-B | Arylamine Derivatives as TTX-S Blockers | 拉夸里亚创药株式会社 | 2016-10-12 | — | — | CN | disclosed |
| CN-103755720-B | Thienopyrimidine derovatives as TRPA1 regulator | 格兰马克药品股份有限公司 | 2016-07-06 | — | — | CN | disclosed |
| CN-103249721-A | Arylamine Derivatives as TTX-S Blockers | RAQUALIA PHARMA INC | 2013-08-14 | — | — | CN | disclosed |
| US-20130177529-A1 | Pyrazole Compounds | VIVOQUEST, INC. | 2013-07-11 | — | — | US | disclosed |
| CN-102369190-A | Triazole derivatives as vasopressin-receptor inhibitors for treating cardiac insufficiency | BAYER SCHERING PHARMA AG | 2012-03-07 | — | — | CN | disclosed |
| CN-100395234-C | Novel CB1 receptor inverse agonists | HOFFMANN LA ROCHE (CH) | 2008-06-18 | — | — | CN | disclosed |
| US-20080076771-A1 | Thrombopoietin Receptor Agonists | REITER LAWRENCE A | 2008-03-27 | — | — | US | disclosed |
| CN-101012193-A | Novel CB 1 receptour inverse agonists | HOFFMANN LA ROCHE (CH) | 2007-08-08 | — | — | CN | disclosed |
| EP-1794156-A2 | TROMBOPOIETIN RECEPTOR AGONISTS | Pfizer Products Incorporated (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006033005-A2 | THROMBOPOIETIN RECEPTOR AGONISTS | PFIZER PRODUCTS INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| CN-1735593-A | Novel CB1 receptor inverse agonists | HOFFMANN LA ROCHE (CH) | 2006-02-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130177529-A1 | Pyrazole Compounds | MAVS, EIF2AK2, ZC3HAV1 | CTSS 1759/4885TAS1R3 2298/4885TAS1R1 3043/4885 |
| US-20080076771-A1 | Thrombopoietin Receptor Agonists | MPL, THPO, TBXA2R | CTSS 3979/4885TAS1R3 1642/4885TAS1R1 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.